1) as compared to the standard drug (Atorvastatin in this study). The liver weight of mice increased (P>1) in all treatment groups relative to standard drug fed group. The plasma lipids such as triglyceride and LDL-cholesterol were found to be increased (P>1) in Test compound 1, test compound 2 , test compound 3 and HFD fed mice when compared to that of standard drug ( Atorvastatin) fed mice. But high-density lipoprotein (HDL) cholesterol increased in standard when compared to that of lab diet fed mice, HFD and test compounds. In conclusion, the supplementation of semi synthetic phenolic compounds may have a weak potential of hypolipidemic effect on mice fed high-fat diet."> 1) as compared to the standard drug (Atorvastatin in this study). The liver weight of mice increased (P>1) in all treatment groups relative to standard drug fed group. The plasma lipids such as triglyceride and LDL-cholesterol were found to be increased (P>1) in Test compound 1, test compound 2 , test compound 3 and HFD fed mice when compared to that of standard drug ( Atorvastatin) fed mice. But high-density lipoprotein (HDL) cholesterol increased in standard when compared to that of lab diet fed mice, HFD and test compounds. In conclusion, the supplementation of semi synthetic phenolic compounds may have a weak potential of hypolipidemic effect on mice fed high-fat diet.">
[go: up one dir, main page]
IDEAS home Printed from https://ideas.repec.org/a/zib/zbnmsp/v1y2017i1p12-16.html
   My bibliography  Save this article

Lipid lowering effect of synthetic phenolic compound in a high- fat diet (HFD) induced hyperlipidemic mice

Author

Listed:
  • Sadaf Nawaz

    (Department of pharmacy, University of Lahore, 38040, Pakistan)

  • Munazza shareef

    (Institute of Pharmacy, Physiology & Pharmacology,University of Agriculture, 38040 Faisalabad, Pakistan)

  • Hina shahid

    (Department of pharmacy, University of Lahore, 38040, Pakistan)

  • Misbah Mushtaq

    (Department of pharmacy, University of Lahore, 38040, Pakistan)

  • Sanaullah Sajid

    (Institute of Microbiology, Faculty of veterinary science, University of Agriculture, Faisalabad, Pakistan)

  • Maliha sarfraz

    (Institute of Pharmacy, Physiology & Pharmacology,University of Agriculture, 38040 Faisalabad, Pakistan)

Abstract
Hyperlipidemia is the major risk factor of arteriosclerosis, coronary heart diseases and death. Phenolic compounds have been shown to offer the protection against cardiovascular complications. In the present study, we studied the effect of semisynthetic phenolic compounds on the hyperlipidemic mice fed with high fat diet (cholesterol, cholic acid and peanut oil). Phenolic compounds were mixed with HFD and the dose of the test compounds were 1 0mg/kg for 6 weeks. After 6 weeks, the average body weight of lab diet, HFD, standard and test compounds were evaluated. Average body weight of test compound 1, test compound 2 and test compound 3 showed insignificant results (P>1) as compared to the standard drug (Atorvastatin in this study). The liver weight of mice increased (P>1) in all treatment groups relative to standard drug fed group. The plasma lipids such as triglyceride and LDL-cholesterol were found to be increased (P>1) in Test compound 1, test compound 2 , test compound 3 and HFD fed mice when compared to that of standard drug ( Atorvastatin) fed mice. But high-density lipoprotein (HDL) cholesterol increased in standard when compared to that of lab diet fed mice, HFD and test compounds. In conclusion, the supplementation of semi synthetic phenolic compounds may have a weak potential of hypolipidemic effect on mice fed high-fat diet.

Suggested Citation

  • Sadaf Nawaz & Munazza shareef & Hina shahid & Misbah Mushtaq & Sanaullah Sajid & Maliha sarfraz, 2017. "Lipid lowering effect of synthetic phenolic compound in a high- fat diet (HFD) induced hyperlipidemic mice," Matrix Science Pharma (MSP), Zibeline International Publishing, vol. 1(1), pages 12-16, February.
    • Handle: RePEc:zib:zbnmsp:v:1:y:2017:i:1:p:12-16
    DOI: 10.26480/msp.01.2017.12.16
    as

    Download full text from publisher

    File URL: https://matrixscpharma.com/download/708/
    Download Restriction: no
    File URL: https://libkey.io/10.26480/msp.01.2017.12.16?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:zib:zbnmsp:v:1:y:2017:i:1:p:12-16. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Zibeline International Publishing (email available below). General contact details of provider: https://matrixscpharma.com/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.